Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has received approval from China's National Medical Products Administration for its Oseltamivir Phosphate Oral Suspension (6 mg/mL), developed in partnership with Yabao Pharmaceuticals. This marks Lupin's first product entry into China, one of the world's largest pharmaceutical markets. The drug is indicated for treatment and prevention of influenza A and B in patients ranging from 2 weeks to 1 year and older. The product will be commercialized with a focus on paediatric use, expanding access to affordable medicines. The partnership with Yabao, a leader in China's paediatric medicine market, represents a strategic expansion of Lupin's global footprint beyond its current presence in over 100 markets.
This approval is positive for shareholders as it opens a massive new revenue market for Lupin, diversifying its geographic presence beyond India and the U.S. While no revenue figures were disclosed, entering China represents a significant long-term growth opportunity for the pharma company.